studies

la/mBC - HER2 positive - 2nd Line (L2), trastuzumab emtansine vs. antibody–drug conjugate, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsDESTINY Breast03, 2022 (REV) 1.82 [1.18; 2.81] 1.82[1.18; 2.81]DESTINY Breast03, 2022 (REV)10%NAnot evaluable progression or deaths (PFS)detailed resultsDESTINY Breast03, 2022 (REV) 3.57 [2.75; 4.63] 3.57[2.75; 4.63]DESTINY Breast03, 2022 (REV)10%NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-06-30 13:07 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 317 - treatments: 1100

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons